1 T. Lindahl, M.S. Satoh, G.G. Poirier, et al.Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks Trends Biochem Sci, 20 (10) (1995), pp. 405-411

2 B.A. Gibson, W.L. KrausNew insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nat Rev Mol Cell Biol, 13 (7) (2012), pp. 411-424

3 J.C. Amé, C. Spenlehauer, G. de MurciaThe PARP superfamily Bioessays, 26 (8) (2004), pp. 882-893

4 P.O. Hassa, M.O. HottigerThe diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases Front Biosci, 13 (2008), pp. 3046-3082

5 M.F. Langelier, J.L. Planck, S. Roy, et al.Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1 Science, 336 (6082) (2012), pp. 728-732

6 M.F. Langelier, J.M. PascalPARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis Curr Opin Struct Biol, 23 (1) (2013), pp. 134-143

7 K.W. CaldecottMammalian DNA base excision repair: dancing in the moonlight DNA Repair, 93 (2020), Article 102921

8 W.A. Beard, J.K. Horton, R. Prasad, et al.Eukaryotic base excision repair: new approaches shine light on mechanism Annu Rev Biochem, 88 (2019), pp. 137-162

9 A.A. Demin, K. Hirota, M. Tsuda, et al.XRCC1 prevents toxic PARP1 trapping during DNA base excision repair Mol Cell, 81 (14) (2021), pp. 3018-3030.e5

10 Y. Gao, C. Li, L. Wei, et al.SSRP1 cooperates with PARP and XRCC1 to facilitate single-strand DNA break repair by chromatin priming Cancer Res, 77 (10) (2017), pp. 2674-2685

11 Q. Chen, K. Ma, X. Liu, et al.Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis Cell Discov, 8 (2022), p. 3

12 B.A. Gibson, Y. Zhang, H. Jiang, et al.Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation Science, 353 (6294) (2016), pp. 45-50

13 P. Sung, H. KleinMechanism of homologous recombination: mediators and helicases take on regulatory functions Nat Rev Mol Cell Biol, 7 (10) (2006), pp. 739-750

14 T.A. Yap, S.K. Sandhu, C.P. Carden, et al.Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic CA Cancer J Clin, 61 (1) (2011), pp. 31-49

15 W.H. Ang, M. Myint, S.J. LippardTranscription inhibition by platinum-DNA cross-links in live mammalian cells J Am Chem Soc, 132 (21) (2010), pp. 7429-7435

16 P.C. Fong, T.A. Yap, D.S. Boss, et al.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol, 28 (15) (2010), pp. 2512-2519

17 J. Ledermann, P. Harter, C. Gourley, et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol, 15 (8) (2014), pp. 852-861

18 E. Pujade-Lauraine, J.A. Ledermann, F. Selle, et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21):a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol, 18 (9) (2017), pp. 1274-1284

19 M. Citarelli, S. Teotia, R.S. LambEvolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes BMC Evol Biol, 10 (2010), p. 308

20 J.P. Gagné, M. Isabelle, K.S. Lo, et al.Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes Nucleic Acids Res, 36 (22) (2008), pp. 6959-6976

21 S.F. El-Khamisy, M. Masutani, H. Suzuki, et al.A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage Nucleic Acids Res, 31 (19) (2003), pp. 5526-5533

22 C.J. Lord, A. AshworthPARP inhibitors: synthetic lethality in the clinic Science, 355 (6330) (2017), pp. 1152-1158

23 N.A.W. Bell, P.J. Haynes, K. Brunner, et al.Single-molecule measurements reveal that PARP1 condenses DNA by loop stabilization Sci Adv, 7 (33) (2021), Article eabf3641

24 M.F. Langelier, T. Eisemann, A.A. Riccio, et al.PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification Curr Opin Struct Biol, 53 (2018), pp. 187-198

25 L. Zandarashvili, M.F. Langelier, U.K. Velagapudi, et al.Structural basis for allosteric PARP-1 retention on DNA breaks Science, 368 (6486) (2020), Article eaax6367

26 T. HelledayThe underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings Mol Oncol, 5 (4) (2011), pp. 387-393

27 N. Saleh-Gohari, H.E. Bryant, N. Schultz, et al.Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks Mol Cell Biol, 25 (16) (2005), pp. 7158-7169

28 D.B. Krastev, S. Li, Y. Sun, et al.The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin Nat Cell Biol, 24 (1) (2022), pp. 62-73

29 K. Cong, M. Peng, A.N. Kousholt, et al.Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency Mol Cell, 81 (15) (2021), pp. 3128-3144.e7

30 L.K. Saha, Y. Murai, S. Saha, et al.Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes Nucleic Acids Res, 49 (18) (2021), pp. 10493-10506

31 J. Mateo, C.J. Lord, V. Serra, et al.A decade of clinical development of PARP inhibitors in perspective Ann Oncol, 30 (9) (2019), pp. 1437-1447

32 M.P. Dias, S.C. Moser, S. Ganesan, et al.Understanding and overcoming resistance to PARP inhibitors in cancer therapy Nat Rev Clin Oncol, 18 (12) (2021), pp. 773-791

33 P.C. Fong, D.S. Boss, T.A. Yap, et al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med, 361 (2) (2009), pp. 123-134

34 S. Banerjee, K.N. Moore, N. Colombo, et al.Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004):5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol, 22 (12) (2021), pp. 1721-1731

35 J.S. Frenel, J.W. Kim, N. Aryal, et al.Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial Ann Oncol, 33 (10) (2022), pp. 1021-1028

36 A.G. Robinson, J.P. Izard, F.E. Vera-BadilloTreatment and patient selection for patients with metastatic castration-resistant prostate after progression on docetaxel and abiraterone/enzalutamide: when to play your CARD and when to do your PARP Eur Urol, 80 (2) (2021), pp. 123-126

37 J. Mateo, N. Porta, D. Bianchini, et al.Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Lancet Oncol, 21 (1) (2020), pp. 162-174

38 S. Carreira, N. Porta, S. Arce-Gallego, et al.Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial Cancer Discov, 11 (11) (2021), pp. 2812-2827

39 J. de Bono, J. Mateo, K. Fizazi, et al.Olaparib for metastatic castration-resistant prostate cancer N Engl J Med, 382 (22) (2020), pp. 2091-2102

40 J. Mateo, S. Carreira, S. Sandhu, et al.DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med, 373 (18) (2015), pp. 1697-1708

41 T. Golan, P. Hammel, M. Reni, et al.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer N Engl J Med, 381 (4) (2019), pp. 317-327

42 K.A. Reiss, R. Mick, M.H. O'Hara, et al.Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2 J Clin Oncol, 39 (22) (2021), pp. 2497-2505

43 E.M. Swisher, T.T. Kwan, A.M. Oza, et al.Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Nat Commun, 12 (2021), p. 2487

44 A. González-Martín, B. Pothuri, I. Vergote, et al.Niraparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med, 381 (25) (2019), pp. 2391-2402

45 M.R. Mirza, B.J. Monk, J. Herrstedt, et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer N Engl J Med, 375 (22) (2016), pp. 2154-2164

46 X. Ai, Y. Pan, J. Shi, et al.Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study J Thorac Oncol, 16 (8) (2021), pp. 1403-1414

47 J.K. Litton, H.S. Rugo, J. Ettl, et al.Talazoparib in patients with advanced breast cancer and a germline BRCA mutation N Engl J Med, 379 (8) (2018), pp. 753-763

48 J.S. de Bono, N. Mehra, G.V. Scagliotti, et al.Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial Lancet Oncol, 22 (9) (2021), pp. 1250-1264

49 N. Li, H. Bu, J. Liu, et al.An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer Clin Cancer Res, 27 (9) (2021), pp. 2452-2458

50 N. Li, Y. Zhang, J. Wang, et al.Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial J Clin Oncol, 40 (22) (2022), pp. 2436-2446

51 J. Murai, S.Y.N. Huang, B.B. Das, et al.Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res, 72 (21) (2012), pp. 5588-5599

52 G.E. Ronson, A.L. Piberger, M.R. Higgs, et al.PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation Nat Commun, 9 (2018), p. 746

53 G. Papeo, H. Posteri, D. Borghi, et al.Discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy J Med Chem, 58 (17) (2015), pp. 6875-6898

54 J.W. Johannes, A. Balazs, D. Barratt, et al.Discovery of 5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs J Med Chem, 64 (19) (2021), pp. 14498-14512

55 G. Illuzzi, A.D. Staniszewska, S.J. Gill, et al.Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper Clin Cancer Res, 28 (21) (2022), pp. 4724-4736

56 T.A. Yap, S. Im, A.M. Schram, et al.PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations Presented at American Association for Cancer Research Annual Meeting (2022)

57 C. Cruz, M. Castroviejo-Bermejo, S. Gutiérrez-Enríquez, et al.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer Ann Oncol, 29 (5) (2018), pp. 1203-1210

58 S. Rottenberg, J.E. Jaspers, A. Kersbergen, et al.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci U S A, 105 (44) (2008), pp. 17079-17084

59 A.L. Heeke, J. Xiu, A. Elliott, et al.Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway Breast Cancer Res Treat, 184 (2) (2020), pp. 265-275

60 P.A. Konstantinopoulos, R. Ceccaldi, G.I. Shapiro, et al.Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer Cancer Discov, 5 (11) (2015), pp. 1137-1154

61 H. Zong, J. Zhang, Z. Xu, et al.Comprehensive analysis of somatic reversion mutations in homologous recombination repair (HRR) genes in A large cohort of Chinese pan-cancer patients J Cancer, 13 (4) (2022), pp. 1119-1129

62 J.E. Ang, C. Gourley, C.B. Powell, et al.Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study Clin Cancer Res, 19 (19) (2013), pp. 5485-5493

63 B. Weigelt, I. Comino-Méndez, I. de Bruijn, et al.Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer Clin Cancer Res, 23 (21) (2017), pp. 6708-6720

64 A.G. Waks, O. Cohen, B. Kochupurakkal, et al.Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer Ann Oncol, 31 (5) (2020), pp. 590-598

65 L. Tobalina, J. Armenia, E. Irving, et al.A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance Ann Oncol, 32 (1) (2021), pp. 103-112

66 D. Quigley, J.J. Alumkal, A.W. Wyatt, et al.Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors Cancer Discov, 7 (9) (2017), pp. 999-1005

67 K.K. Lin, M.I. Harrell, A.M. Oza, et al.BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma Cancer Discov, 9 (2) (2019), pp. 210-219

68 Z. Mirman, T. de Lange53BP1:a DSB escort Genes Dev, 34 (1–2) (2020), pp. 7-23

69 D. Setiaputra, D. DurocherShieldin - the protector of DNA ends EMBO Rep, 20 (5) (2019), Article e47560

70 S. Panier, S.J. BoultonDouble-strand break repair: 53BP1 comes into focus Nat Rev Mol Cell Biol, 15 (1) (2014), pp. 7-18

71 Z. Mirman, N.K. Sasi, A. King, et al.53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis Nat Cell Biol, 24 (1) (2022), pp. 51-61

72 S.M. Noordermeer, S. Adam, D. Setiaputra, et al.The shieldin complex mediates 53BP1-dependent DNA repair Nature, 560 (7716) (2018), pp. 117-121

73 H. Dev, T.W.W. Chiang, C. Lescale, et al.Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells Nat Cell Biol, 20 (8) (2018), pp. 954-965

74 Y.J. He, K. Meghani, M.C. Caron, et al.DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells Nature, 563 (7732) (2018), pp. 522-526

75 J. Tan, X. Zheng, M. Li, et al.C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer Oncogene, 40 (22) (2021), pp. 3845-3858

76 A.R. Chaudhuri, E. Callen, X. Ding, et al.Replication fork stability confers chemoresistance in BRCA-deficient cells Nature, 535 (7612) (2016), pp. 382-387

77 A. Taglialatela, S. Alvarez, G. Leuzzi, et al.Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers Mol Cell, 68 (2) (2017), pp. 414-430.e8

78 B. Rondinelli, E. Gogola, H. Yücel, et al.EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation Nat Cell Biol, 19 (11) (2017), pp. 1371-1378

79 J. Veeck, S. Ropero, F. Setien, et al.BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors J Clin Oncol, 28 (29) (2010), pp. e563-e564 author reply e565-6

80 A. Dobrovic, D. SimpfendorferMethylation of the BRCA1 gene in sporadic breast cancer Cancer Res, 57 (16) (1997), pp. 3347-3350

81 A. AshworthA synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol, 26 (22) (2008), pp. 3785-3790

82 O. Kondrashova, M. Topp, K. Nesic, et al.Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma Nat Commun, 9 (2018), p. 3970

83 K. Nesic, O. Kondrashova, R.M. Hurley, et al.Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma Cancer Res, 81 (18) (2021), pp. 4709-4722

84 J. Gao, B.A. Aksoy, U. Dogrusoz, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal, 6 (269) (2013), p. pl1

85 K. Wilke, S. Wiemann, R. Gaul, et al.Isolation of human and mouse HMG2a cDNAs: evidence for an HMG2a-specific 3' untranslated region Gene, 198 (1–2) (1997), pp. 269-274

86 Z. Li, Y. Zhang, S. Sui, et al.Targeting HMGB3/hTERT axis for radioresistance in cervical cancer J Exp Clin Cancer Res, 39 (2020), p. 243

87 X. Li, Y. Wu, A. Liu, et al.miR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3 Biochem Biophys Res Commun, 477 (4) (2016), pp. 768-773

88 A. Mukherjee, V. Huynh, K. Gaines, et al.Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin Cancer Res, 79 (13) (2019), pp. 3185-3191

89 H. Ma, G. Qi, F. Han, et al.HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer Cell Death Dis, 13 (3) (2022), p. 263

90 H. Yu, M. Kortylewski, D. PardollCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment Nat Rev Immunol, 7 (1) (2007), pp. 41-51

91 S. Zou, Q. Tong, B. Liu, et al.Targeting STAT3 in cancer immunotherapy Mol Cancer, 19 (2020), p. 145

92 L. Ding, X. Chen, X. Xu, et al.PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3 Cancer Immunol Res, 7 (1) (2019), pp. 136-149

93 A. Martincuks, J. Song, A. Kohut, et al.PARP inhibition activates STAT3 in both tumor and immune cells underlying therapy resistance and immunosuppression in ovarian cancer Front Oncol, 11 (2021), Article 724104

94 A. Färkkilä, A. Rodríguez, J. Oikkonen, et al.Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells Cancer Res, 81 (10) (2021), pp. 2774-2787

95 E.M. Hammond, M.C. Asselin, D. Forster, et al.The meaning, measurement and modification of hypoxia in the laboratory and the clinic Clin Oncol, 26 (5) (2014), pp. 277-288

96 J.M. BrownExploiting the hypoxic cancer cell: mechanisms and therapeutic strategies Mol Med Today, 6 (4) (2000), pp. 157-162

97 M. Mehibel, Y. Xu, C.G. Li, et al.Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models J Clin Invest, 131 (11) (2021), Article e146256

98 N. Chan, I.M. Pires, Z. Bencokova, et al.Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment Cancer Res, 70 (20) (2010), pp. 8045-8054

99 M. Gachechiladze, J. Škarda, A. Soltermann, et al.RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies Int J Cancer, 141 (7) (2017), pp. 1286-1294

100 M. Castroviejo-Bermejo, C. Cruz, A. Llop-Guevara, et al.A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation EMBO Mol Med, 10 (12) (2018), Article e9172

101 B. Pellegrino, A. Herencia-Ropero, A. Llop-Guevara, et al.Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification Cancer Res, 82 (8) (2022), pp. 1646-1657

102 Y. Liu, M.L. Burness, R. Martin-Trevino, et al.RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer Clin Cancer Res, 23 (2) (2017), pp. 514-522

103 A.L. Heeke, M.J. Pishvaian, F. Lynce, et al.Prevalence of homologous recombination-related gene mutations across multiple cancer types JCO Precis Oncol (2018) 2018:PO.17.00286

104 M.B. Ipsen, E.M.G. Sørensen, E.A. Thomsen, et al.A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer Oncogene, 41 (37) (2022), pp. 4271-4281

105 Y. Peng, Q. Liao, W. Tan, et al.The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors Nat Commun, 10 (2019), p. 1224

106 C. Sun, Y. Fang, J. Yin, et al.Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers Sci Transl Med, 9 (392) (2017), Article eaal5148

107 B. Yang, X. Li, Y. Fu, et al.MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors Cancer Res, 81 (10) (2021), pp. 2714-2729

108 M. Paes Dias, V. Tripathi, I. van der Heijden, et al.Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps Mol Cell, 81 (22) (2021), pp. 4692-4708

109 A. Taglialatela, G. Leuzzi, V. Sannino, et al.REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps Mol Cell, 81 (19) (2021), pp. 4008-4025

110 S.H. Chen, X. YuTargeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies Sci Adv, 5 (4) (2019), Article eaav4340

111 K. Parmar, B.S. Kochupurakkal, J.B. Lazaro, et al.The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition Clin Cancer Res, 25 (20) (2019), pp. 6127-6140

112 S. Zhou, D. Li, D. Xiao, et al.Inhibition of PKM2 enhances sensitivity of olaparib to ovarian cancer cells and induces DNA damage Int J Biol Sci, 18 (4) (2022), pp. 1555-1568

113 A. Kanakkanthara, X. Hou, T.L. Ekstrom, et al.Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma Cancer Res, 82 (2) (2022), pp. 307-319

114 R. Gabbasov, I.D. Benrubi, S.W. O'Brien, et al.Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition Cancer Biol Ther, 20 (7) (2019), pp. 1035-1045

115 Q. Wang, J.S. Bergholz, L. Ding, et al.STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer Nat Commun, 13 (2022), p. 3022

116 L. Li, S. Karanika, G. Yang, et al.Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer Sci Signal, 10 (480) (2017), Article eaam7479

117 K. Fugger, I. Bajrami, M. Silva Dos Santos, et al.Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors Science, 372 (6538) (2021), pp. 156-165

118 S. Li, L. Wang, Y. Wang, et al.The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment J Hematol Oncol, 15 (2022), p. 147

119 N. Gupta, T.T. Huang, S. Horibata, et al.Cell cycle checkpoints and beyond: exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer Pharmacol Res, 178 (2022), Article 106162

120 H. Kim, H. Xu, E. George, et al.Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models Nat Commun, 11 (2020), p. 3726

121 R.A. Sharma, R. Plummer, J.K. Stock, et al.Clinical development of new drug-radiotherapy combinations Nat Rev Clin Oncol, 13 (10) (2016), pp. 627-642

122 S.J. Veuger, J.E. Hunter, B.W. DurkaczIonizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance Oncogene, 28 (6) (2009), pp. 832-842

123 M.T. Boudra, C. Bolin, S. Chiker, et al.PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels Cell Mol Life Sci, 72 (8) (2015), pp. 1585-1597

124 Y. Mao, X. Huang, Z. Shuang, et al.PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation Cancer Med, 7 (4) (2018), pp. 1285-1296

125 Y. Bi, I.I. Verginadis, S. Dey, et al.Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas Gynecol Oncol, 150 (3) (2018), pp. 534-544

126 M. Mangoni, M. Sottili, G. Salvatore, et al.Enhancement of soft tissue sarcoma cell radiosensitivity by poly(ADP-ribose) polymerase-1 inhibitors Radiat Res, 190 (5) (2018), pp. 464-472

127 R. Abbotts, M.J. Topper, C. Biondi, et al.DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation Proc Natl Acad Sci U S A, 116 (45) (2019), pp. 22609-22618

128 A. Wilson, V. Menon, Z. Khan, et al.Nitric oxide-donor/PARP-inhibitor combination: a new approach for sensitization to ionizing radiation Redox Biol, 24 (2019), Article 101169

129 C.V.M. Verhagen, R. de Haan, F. Hageman, et al.Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells Radiother Oncol, 116 (3) (2015), pp. 358-365

130 S.T. Sizemore, R. Mohammad, G.M. Sizemore, et al.Synthetic lethality of PARP inhibition and ionizing radiation is p53-dependent Mol Cancer Res, 16 (7) (2018), pp. 1092-1102

131 R.S. Riley, C.H. June, R. Langer, et al.Delivery technologies for cancer immunotherapy Nat Rev Drug Discov, 18 (3) (2019), pp. 175-196

132 Z. Wang, K. Sun, Y. Xiao, et al.Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models Sci Rep, 9 (2019), p. 1853

133 U. LassenCombining PARP inhibition with PD-1 inhibitors Lancet Oncol, 20 (9) (2019), pp. 1196-1198

134 S. Vinayak, S.M. Tolaney, L. Schwartzberg, et al.Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer JAMA Oncol, 5 (8) (2019), pp. 1132-1140

135 P.A. Konstantinopoulos, S. Waggoner, G.A. Vidal, et al.Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma JAMA Oncol, 5 (8) (2019), pp. 1141-1149

136 S.K. Sandhu, M. Hussain, J. Mateo, et al.PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations Ann Oncol, 30 (2019), pp. ix188-ix189

137 T.A. Yap, A. Bessudo, E. Hamilton, et al.IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer J Immunother Cancer, 10 (3) (2022), Article e003924

138 T. Powles, D. Carroll, S. Chowdhury, et al.An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer Nat Med, 27 (5) (2021), pp. 793-801

139 A. Färkkilä, D.C. Gulhan, J. Casado, et al.Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer Nat Commun, 11 (1) (2020), p. 1459